Claims for Patent: 9,771,358

Summary for Patent: 9,771,358

Title:	Dihydropyrimidine compounds and their application in pharmaceuticals
Abstract:	Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases. ##STR00001##
Inventor(s):	Zhang; Yingjun (Dongguan, CN), Ren; Qingyun (Dongguan, CN), Liu; Xinchang (Dongguan, CN), Goldmann; Siegfried (Dongguan, CN)
Assignee:	SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)
Application Number:	15/116,226
Patent Claims:	1. A compound of Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, a prodrug, a stereoisomer, an N-oxide, or a pharmaceutically acceptable salt thereof, ##STR00202## wherein each R.sup.1 is independently H, F, Cl, Br, I, nitro, trifluoromethyl or cyano; each R.sup.2 is independently methyl or ethyl; each R.sup.3 is independently thiazolyl, oxazolyl or imidazolyl; wherein optionally each of thiazolyl, oxazolyl and imidazolyl is independently unsubstituted or substituted with methyl or cyclopropyl; each Z is independently O or S; each R.sup.4 is independently --(CR.sup.5R.sup.5a).sub.t--C(.dbd.O)--OH; each R.sup.4a is independently H, methyl or isopropyl; each R.sup.5 and R.sup.5a is independently H, F or methyl, or R.sup.5 and R.sup.5a, together with the carbon atom to which they are attached, form cyclopropyl or --C(.dbd.O); wherein each n is independently 1, 2 or 3; each m is independently 0, 1 or 2; and t is 1, 2, 3 or 4. 2. The compound according to claim 1, wherein R.sup.3 is ##STR00203## 3. The compound according to claim 1 having one of the following structures: ##STR00204## ##STR00205## ##STR00206## ##STR00207## ##STR00208## ##STR00209## ##STR00210## ##STR00211## ##STR00212## ##STR00213## ##STR00214## ##STR00215## ##STR00216## ##STR00217## ##STR00218## ##STR00219## ##STR00220## ##STR00221## ##STR00222## ##STR00223## ##STR00224## ##STR00225## ##STR00226## ##STR00227## ##STR00228## ##STR00229## ##STR00230## ##STR00231## ##STR00232## ##STR00233## ##STR00234## ##STR00235## ##STR00236## ##STR00237## ##STR00238## ##STR00239## ##STR00240## ##STR00241## ##STR00242## ##STR00243## ##STR00244## ##STR00245## ##STR00246## ##STR00247## ##STR00248## ##STR00249## ##STR00250## ##STR00251## ##STR00252## ##STR00253## ##STR00254## ##STR00255## ##STR00256## ##STR00257## ##STR00258## ##STR00259## ##STR00260## ##STR00261## ##STR00262## ##STR00263## ##STR00264## or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, a prodrug, a stereoisomer, an N-oxide, or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound according to claim 1. 5. The pharmaceutical composition according to claim 4 further comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 6. The pharmaceutical composition according to claim 4 further comprises an anti-HBV agent. 7. The pharmaceutical composition according to claim 6, wherein the anti-HBV agent is an HBV polymerase inhibitor, immunomodulator or interferon. 8. The pharmaceutical composition according to claim 6, wherein the anti-HBV agent is lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon .alpha.-1b, interferon .alpha., interferon .alpha.-2a, interferon .beta.-1a, interferon .alpha.-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon .alpha.-2b, levamisole, or propagermanium. 9. A method for managing, treating or lessening an HBV disease comprising administrating to a patient a therapeutically effective amount of the compound according to claim 1. 10. The method according to claim 9, wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection. 11. The method according to claim 10, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma. 12. A method for managing, treating or lessening an HBV disease comprising administrating to a patient a therapeutically effective amount of the pharmaceutical composition according to claim 4. 13. The method according to claim 12, wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection. 14. The method according to claim 13, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma. 15. The compound according to claim 1 having one of the following structures: ##STR00265## or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, a prodrug, a stereoisomer, an N-oxide, or a pharmaceutically acceptable salt thereof. 16. The compound according to claim 15, wherein the compound is a pharmaceutically acceptable salt. 17. The compound according to claim 16, wherein the pharmaceutically acceptable salt is an organic or inorganic salt. 18. The compound according to claim 16, wherein the pharmaceutically acceptable salt is hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, acetate, oxalate, maleate, tartarate, citrate, succinate, malonate, adipate, 2-hydracrylic acid salt, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphanic acid salt, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, or valerate salts.

Details for Patent 9,771,358

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	06/04/1986		2034-03-28
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2034-03-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2034-03-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2034-03-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2034-03-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2034-03-28